Salisbury Foundation Trust

FOI_5275

Internal Reference Number: FOI_5275

Date Request Received: 08/09/2019 07:46:12

Date Request Replied To: 02/10/2019 09:23:18

This response was sent via: By Email

Request Summary: Squamous and non Squamous Cell Non-small cell lung cancer

Request Category: Private Individuals

 
Question Number 1:
In the past 3 months, how many Squamous Cell Non-small cell lung cancer (SqNSCLC) patients were treated with:
Afatinib
Atezolizumab monotherapy
Bevacizumab
Docetaxel monotherapy
Durvalumab
Erlotinib
Gemcitabine
Necitumumab
Nivolumab
Paclitaxel
Pembrolizumab monotherapy
Pembrolizumab chemo in combination
Pemetrexed
Ramucirumab
Vinorelbine and cisplatin / carboplatin
Other active systemic anti-cancer therapy [please state]
Palliative care only
 
Answer To Question 1:
We are only able to provide data for lung cancer as a whole so haven’t been able to separate based on histology.

In the past 3 months, how many Squamous Cell Non-small cell lung cancer (SqNSCLC) patients were treated with:
Afatinib 4
Atezolizumab monotherapy8
Bevacizumab 0
Docetaxel monotherapy 3
Durvalumab 0
Erlotinib 2
Gemcitabine 5
Necitumumab 0
Nivolumab 0
Paclitaxel 0
Pembrolizumab monotherapy 11
Pembrolizumab chemo in combination 0
Pemetrexed 7
Ramucirumab 0
Vinorelbine and cisplatin / carboplatin 7
Other active systemic anti-cancer therapy [please state]
Palliative care only- unable to answer as they won’t have received chemo!
 
Question Number 2:
n the past 3 months, how many Non Squamous Cell Non-small cell lung cancer (Non SqNSCLC) patients were treated with:
Afatinib
Alectinib
Atezolizumab mono
Atezolizumab + bevacizumab + carboplatin + paclitaxel
Bevacizumab
Brigatinib
Ceritinib
Crizotinib
Dacomitinib
Docetaxel monotherapy
Erlotinib
Gefitinib
Nintedanib with docetaxel
Nivolumab
Osimertinib
Paclitaxel
Pembrolizumab monotherapy
Pembrolizumab chemo in combination
Pemetrexed with carboplatin
Pemetrexed with cisplatin
Ramucirumab
Other active systemic anti-cancer therapy [please state]
Palliative care only
 
Answer To Question 2:
We are only able to provide data for lung cancer as a whole so haven’t been able to separate based on histology.

n the past 3 months, how many Non Squamous Cell Non-small cell lung cancer (Non SqNSCLC) patients were treated with:
Afatinib see above
Alectinib 2
Atezolizumab mono see above
Atezolizumab + bevacizumab + carboplatin + paclitaxel 0
Bevacizumab 0
Brigatinib 0
Ceritinib 0
Crizotinib 1
Dacomitinib 0
Docetaxel monotherapy see above
Erlotinib see above
Gefitinib 3
Nintedanib with docetaxel 1
Nivolumab see above
Osimertinib 0
Paclitaxel see above
Pembrolizumab monotherapy see above
Pembrolizumab chemo in combination see above
Pemetrexed with carboplatin 4
Pemetrexed with cisplatin 1
Ramucirumab see above
Other active systemic anti-cancer therapy [please state]
Palliative care only
Other SACT total 8 patients (7 carboplatin/etoposide, 1 topotecan)
 
To return to the list of all the FOI requests please click here

Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.

Salisbury NHS Foundation Trust, Salisbury District Hospital, Salisbury, Wiltshire, SP2 8BJ
T: 01722 336262 E: sft.pals@nhs.net
© 2021 Salisbury NHS Foundation Trust
Trust Values